Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules

• US 20030198619A1
• Filed: 12/18/2002
• Published: 10/23/2003
• Est. Priority Date: 12/19/2001
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Nguyen, Vu A., Daddona, Peter E., Wong, Patrick S.L., Dong, Liang C., Yum, Si-Hong Alicia, Chao, Anthony C.
• Application Number:
  US10/324,154
• Publication Number:
  US 20030198619A1
• Time in Patent Office: Days
• US Class Current: 424/85.7
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/1274 Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/4891 Coated capsules; Multilayered drug free capsule shells with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention includes a formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules. The formulation of the present invention includes a permeation enhancer, a hydrophilic macromolecule, and a carrier that exhibits in-situ gelling properties, such as a nonionic surfactant. The formulation of the present invention is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation of the present invention presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. The dosage form of the present invention incorporates the formulation of the present invention and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time.

Claims

1. A formulation for increasing the bioavailability of an orally administered hydrophilic macromolecule, the formulation comprising a hydrophilic macromolecule, a permeation enhancer, and a carrier capable of forming a bioadhesive gel, the formulation being formulated such that the formulation is released within the gastrointestinal tract as a liquid and forms a bioadhesive gel in-situ after the formulation has had some opportunity to spread across the surface of the gastrointestinal mucosal membrane.

2. The formulation of claim 1, wherein the hydrophilic macromolecule comprises a polypeptide.

3. The formulation of claim 2, wherein the polypeptide is selected from a group consisting of insulin, human growth hormone, IFN-α

, samon calcitonin, erythropoietin (EPO), TPA (Activase), G-CSF (Neupogen), Factor VIII (Kogenate), growth hormone-releasing peptide, β

-casomorphine, renin inhibitor, tetragastrin, pepstatinylglycine, leuprolide, empedopeptin, β

-lactoglobulin, TRH analogues, ACE inhibitors, and cyclosporine.

4. The formulation of claim 1, wherein the hydrophilic macromolecule comprises a polysaccharide.

5. The formulation of claim 4, wherein the polysaccharide is selected from a group consisting of pentosan polysulfate sodium (PPS), unfractionated heparin, and low molecular weight heparin (LMWH).

6. The formulation of claim 1, wherein the permeation enhancer comprises a fatty acid permeation enhancer.

7. The formulation of claim 1, wherein the permeation enhancer is selected from a group consisting of ethylene-diamine tetra-acetic acid (EDTA), bile salt permeation enhancers, fatty acid permeation enhancers, acyl carnitines, and salicylates.

8. The formulation of claim 1, wherein the carrier comprises a nonionic surfactant.

9. The formulation of claim 8, wherein the nonionic surfactant is selected from a group consisting of Cremophor EL, Cremophor RH, Incordas 30, polyoxyethylene 5 castor oil, polyethylene 9 castor oil, polyethylene 15 castor oil, d-α

-tocopheryl polyethylene glycol succinate (TPGS), myverol, oleth-3, oleth-5, polyoxyl 10 oleyl ether, oleth-20, steareth-2, stearteth-10, steareth-20, ceteareth-20, polyoxyl 20, cetostearyl ether, PPG-5 ceteth-20, PEG-6 capryl/capric triglyceride, Pluronic®

L10, L31, L35, L42, L43, L44, L62, L61, L63, L72, L81, L101, L121, and L122, Tween 20, Tween 40, Tween 60, Tween 65, Tween 80, Tween 81, Tween 85, PEG 20 almond glycerides, PEG-60 almond glycerides, PEG-20 corn glycerides, and PEG-60 corn glycerides.

10. The formulation of claim 1, wherein the formulation further comprises a viscosity reducing agent.

11. The formulation of claim 10, wherein the viscosity reducing agent is selected from group consisting of polyoxyethylene 5 castor oil, polyoxyethylene 9 castor oil, labratil, labrasol, capmul GMO (glyceryl mono oleate), capmul MCM (medium chain mono- and diglyceride), capmul MCM C8 (glyceryl mono caprylate), capmul MCM C10 (glyceryl mono caprate), capmul GMS-50 (glyceryl mono stearate), caplex 100 (propylene glycol didecanoate), caplex 200 (propylene glycol dicaprylate/dicaprate), caplex 800 (propylene glycol di 2-ethyl hexanoate), captex 300 (glyceryl tricapryl/caprate), captex 1000 (glyceryl tricaprate), captex 822 (glyceryl triandecanoate), captex 350 (glyceryl tricaprylate/caprate/laurate), caplex 810 (glyceryl tricaprylate/caprate/linoleate), capmul PG8 (propylene mono caprylate), propylene glycol, and propylene glycol laurate (PGL).

12. The formulation of claim 1, wherein the formulation further comprises an antioxidant.

13. The formulation of claim 12, wherein the antioxidant is selected from a group consisting of butylated hydroxytoluene, ascorbic acid, fumaric acid, malic acid, ∝

-tocopherol, ascorbic acid palmitate, butylated hydroxyanisole, propyl gallate, sodium ascorbate, and sodium metabisulfate.

14. A formulation for enhancing the bioavailability of an orally administered hydrophilic macromolecule, the formulation comprising a hydrophilic macromolecule, a permeation enhancer, and a carrier capable of forming a bioadhesive gel, wherein the hydrophilic macromolecule comprises between about 0.01 wt % and about 50 wt % of the formulation, the permeation enhancer comprises between about 11% and about 30% of the formulation, and the carrier comprising between about 35% and 88% of the formulation.

15. The formulation of claim 14, wherein the hydrophilic macromolecule, the permeation enhancer, and carrier are included in amounts that allow the formulation to be released within the gastrointestinal tract as a liquid before forming a bioadhesive gel in-situ after the formulation has had some opportunity to spread across a surface of a gastrointestinal mucosal membrane.

16. A dosage form comprising:

a formulation comprising a hydrophilic macromolecule, a permeation enhancer, and a carrier capable of forming a bioadhesive gel, the formulation being formulated such that the formulation is released within the gastrointestinal tract as a liquid and forms a bioadhesive gel in-situ after the formulation has had some opportunity to spread across a surface of a gastrointestinal mucosal membrane; and

a delivery device configured to release the formulation within the gastrointestinal tract of a subject at a controlled rate over a period of time.

17. The dosage form of claim 16, wherein the delivery device is provided with an enteric coating.

18. The dosage form of claim 16, wherein the delivery device comprises:

a capsule;

a deformable barrier layer formed on the gelatin capsule;

an osmotic layer formed on the barrier layer; and

a semipermeable membrane formed over the semipermeable membrane.

19. The dosage form of claim 16, wherein the delivery device comprises:

a capsule having an interior compartment, the interior compartment containing the formulation, an osmotic engine, and a barrier layer positioned between the formulation and the osmotic engine; and

a semipermeable membrane.

20. A controlled release dosage form comprising:

a liquid formulation comprising a hydrophilic macromolecule, the formulation being capable of enhancing the oral bioavailability of the hydrophilic macromolecule; and

a deliver device configured to deliver the formulation over a desired period of time.